Onconova names Avi Oler as VP, corporate development and general counsel
Onconova Therapeutics (ONTX) announced that Abraham "Avi" Oler has joined Onconova's management team as Vice President, Corporate Development and General Counsel. Oler will be primarily responsible for business development, investor relations, and legal affairs of the company. To help further advance Rigosertib, the company's Phase 3 candidate for MDS, Oler's focus will be on forging new collaborations in additional geographies. Rigosertib is currently partnered with SymBio Pharmaceuticals for Japan and Korea, and with Pint Pharma for Latin America. Oler served most recently as Vice President of Operations and Chief of Staff to the CEO of Spectrum Pharmaceuticals (SPPI).